125 related articles for article (PubMed ID: 16673022)
1. Presence of JAK2 V617F tyrosine kinase mutation as a myeloid-lineage-specific mutation in chronic neutrophilic leukaemia.
Lea NC; Lim Z; Westwood NB; Arno MJ; Gäken J; Mohamedali A; Mufti GJ
Leukemia; 2006 Jul; 20(7):1324-6. PubMed ID: 16673022
[No Abstract] [Full Text] [Related]
2. Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.
Mc Lornan DP; Percy MJ; Jones AV; Cross NC; Mc Mullin MF
Haematologica; 2005 Dec; 90(12):1696-7. PubMed ID: 16330446
[TBL] [Abstract][Full Text] [Related]
3. Early relapse of JAK2 V617F-positive chronic neutrophilic leukemia with central nervous system infiltration after unrelated bone marrow transplantation.
Kako S; Kanda Y; Sato T; Goyama S; Noda N; Shoda E; Oshima K; Inoue M; Izutsu K; Watanabe T; Motokura T; Chiba S; Fukayama M; Kurokawa M
Am J Hematol; 2007 May; 82(5):386-90. PubMed ID: 17109389
[TBL] [Abstract][Full Text] [Related]
4. Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon α-2b.
Zhang X; Pan J; Guo J
Acta Haematol; 2013; 130(1):44-6. PubMed ID: 23391844
[TBL] [Abstract][Full Text] [Related]
5. Chronic neutrophilic leukaemia.
Bain BJ
Acta Haematol; 2014; 131(1):45. PubMed ID: 24029118
[No Abstract] [Full Text] [Related]
6. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
7. JAK2 V617F mutation analysis in different myeloid lineages (granulocytes, platelets, CFU-MK, BFU-E and CFU-GM) in essential thrombocythemia patients.
Florensa L; Bellosillo B; Besses C; Puigdecanet E; Espinet B; Pérez-Vila E; Longarón R; Vilà RM; Solé F; Serrano S
Leukemia; 2006 Oct; 20(10):1903-5. PubMed ID: 16888614
[No Abstract] [Full Text] [Related]
8. Nephrotic syndrome related to chronic neutrophilic leukemia.
Wang R; Tong H; Wang H; Chen Z; Wang L; Chen J
Intern Med; 2014; 53(21):2505-9. PubMed ID: 25366011
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals.
Wang YL; Lee JW; Kui JS; Chadburn A; Cross NC; Knowles DM; Coleman M
Acta Haematol; 2007; 118(4):209-14. PubMed ID: 18032883
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
[TBL] [Abstract][Full Text] [Related]
11. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D
Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
[TBL] [Abstract][Full Text] [Related]
12. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
13. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
[TBL] [Abstract][Full Text] [Related]
15. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Rosillo C; Camoriano JK
Am J Hematol; 2007 May; 82(5):400-2. PubMed ID: 17133423
[TBL] [Abstract][Full Text] [Related]
16. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
[TBL] [Abstract][Full Text] [Related]
17. Analysis of gene mutation characteristics in patients with chronic neutrophilic leukaemia.
Yin B; Chen X; Gao F; Li J; Wang HW
Hematology; 2019 Dec; 24(1):538-543. PubMed ID: 31315541
[No Abstract] [Full Text] [Related]
18. No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythaemia vera and concurrent monoclonal B cell disorder.
Stijnis C; Kroes WG; Balkassmi S; Marijt EW; van Rossum AP; Bakker E; Vlasveld LT
Acta Haematol; 2012; 128(3):183-6. PubMed ID: 22890406
[TBL] [Abstract][Full Text] [Related]
19. JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia.
Pich A; Riera L; Sismondi F; Godio L; Davico Bonino L; Marmont F; Francia di Celle P
J Clin Pathol; 2009 Sep; 62(9):798-801. PubMed ID: 19734476
[TBL] [Abstract][Full Text] [Related]
20. Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment.
Henry L; Carillo S; Jourdan E; Arnaud A; Brun S; Lavabre-Bertrand T
Am J Hematol; 2007 Jun; 82(6):500-1. PubMed ID: 17301972
[No Abstract] [Full Text] [Related]
[Next] [New Search]